Goodpasture’s syndrome in 17-year-old patient

Cover Page
  • Authors: Ovsyannikov DY.1, Volkov MY.1, Glazyrina AA2, Marchenkov Y.V3, Gitinov S.A1, Rogatkin PS2, Koltunov IY.1
  • Affiliations:
    1. Peoples Friendship University of Russia
    2. Morozov Children Clinical City Hospital
    3. CDC MEDSI
  • Issue: No 1 (2016)
  • Pages: 166-172
  • Section: Articles
  • URL: http://journals.rudn.ru/medicine/article/view/3756
  • Cite item

Abstract


Goodpasture’s syndrome (GS) is a severe autoimmune disease, which is characterized by kidney and lung affection. Antibodies to glomerular basal membrane (AGBM) are considered to be a specific marker. We present a literature review and a clinical case of GS with typical clinical presentation and low effectiveness of glucocorticosteroid treatment in 17-year-old patient. The disease was characterized by the AGBM disappearance from peripheral blood, positive test for cryoglobulins and improvement of patient condition during therapy with rituximab.

About the authors

D Yu Ovsyannikov

Peoples Friendship University of Russia

Email: mdovsyannikov@yahoo.com
Morozov Children Clinical City Hospital 4th Dobrininskiy ln., 1/9, Moscow, Russia, 119049

M Yu Volkov

Peoples Friendship University of Russia

Email: _de_@mail.ru

A A Glazyrina

Morozov Children Clinical City Hospital

Email: glazyrina.a.a@rambler.ru

Ya V Marchenkov

CDC MEDSI

Email: juroslav@mail.ru

Sh A Gitinov

Peoples Friendship University of Russia

Email: vargant20@mail.ru

P S Rogatkin

Morozov Children Clinical City Hospital

Email: piter_r@mail.ru

I Ye Koltunov

Peoples Friendship University of Russia

Email: mosgorzdrav.ru/mgdkb
Morozov Children Clinical City Hospital 4th Dobrininskiy ln., 1/9, Moscow, Russia, 119049

References

Statistics

Views

Abstract - 230

PDF (Russian) - 592

Cited-By



Copyright (c) 2016 Овсянников Д.Ю., Волков М.Ю., Глазырина А.А., Марченков Я.В., Гитинов Ш.A., Рогаткин П.С., Колтунов И.Е.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies